Browsing "Infectious Diseases" by Keyword : SARS-CoV-2

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 6 to 18 of 18

Pub YearTitleAuthor(s)
2021Effects of early corticosteroid use in patients with severe coronavirus disease 2019김은진
2024Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy김영롱, 정근옥, 허중연
2023Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection허중연
2022Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study허중연
2023Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial김은진, 허중연
2020Interim Guidelines on Antiviral Therapy for COVID-19허중연
2024Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination: Insight into the annual vaccination strategy허중연, 현학준
2023Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations현학준
2023Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study허중연
2022Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial허중연
2022Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network박래웅, 최영화
2023Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity허중연
2022Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment김영롱, 유진세, 허중연
1

Browse